Author

R. Boytz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Assay:bulk RNA-seq· 1 Assay:cryo-EM· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

R. A. Davey· 3 shared C. J. Donahue· 2 shared H. Mori· 2 shared J. Patten· 2 shared A. Baum· 1 shared A. Parvate· 1 shared A. Rafique· 1 shared A.-L. Barabasi· 1 shared

Activity by Year

2021-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

R. A. Davey

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Structure of the Inmazeb cocktail and resistance to escape against Ebola virus

V. Rayaprolu, B. Fulton, A. Rafique, E. Arturo, D. Williams, C. Hariharan, H. Callaway, A. Parvate, S. L. Schendel, D. Parekh, S. Hui, K. Shaffer, K. E. Pascal, E. Wloga, S. Giordano, , E. O. Saphire

The paper presents the cryoEM structure of the Inmazeb cocktail in complex with Ebola virus glycoprotein, showing how the combination prevents escape mutations better than monotherapy.

bioRxiv · Oct 11, 2022Biophysics

CAPG is required for Ebola virus infection by controlling virus egress from infected cells.

H. Mori, J. M. Connell, C. J. Donahue, R. Boytz, J. Patten, D. W. Leung, D. J. Lacount, R. A. Davey

This study identifies CAPG as a host factor required for Ebola virus infection by stabilizing actin filaments and facilitating viral egress from infected cells.

bioRxiv · Apr 10, 2022Microbiology

Brequinar and Dipyridamole in Combination Exhibits Synergistic Antiviral Activity Against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19

J. F. Demarest, M. Kienle, R. Boytz, M. Ayres, E. Kim, D. Chung, V. Gandhi, R. A. Davey, D. B. Sykes, N. Shohdy, J. C. Pottage, V. S. Kumar

This study shows that combining brequinar and dipyridamole synergistically inhibits SARS-CoV-2 replication in vitro by depleting cellular pyrimidine nucleotides.

bioRxiv · Mar 30, 2022Microbiology

Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivo.

J. Patten, P. T. Keiser, D. M. Gysi, G. Menichetti, H. Mori, C. J. Donahue, X. Gan, I. F. do Valle, K. Geoghegan-Barek, M. Anantpadma, R. Boytz, J. L. Berrigan, S. Hulsey-Stubbs, K. T. Ayazika, C. O'Leary, , R. A. Davey

The paper identifies 389 small molecules and 813 host targets that inhibit SARS-CoV-2 infection through in vitro and in vivo testing, using computational integration of drug activity and cellular networks.

bioRxiv · Apr 20, 2021 · PreprintMicrobiology